Drug intelligence / Profile preview

CaPTeR radioligands

Development stage: Preclinical
Lead developer: Merken Biotech
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CaPTeR (Cancer de Páncreas: Terapia de Precisión con Radioligandos) is a preclinical-stage theranostic radiopharmaceutical platform being developed by Merken Biotech in collaboration with PositronMed. The technology is specifically designed to target Pancreatic Ductal Adenocarcinoma (PDAC) by binding to undisclosed molecular targets overexpressed in tumor tissue. The platform utilizes a theranostic approach, employing diagnostic radioligands labeled with isotopes such as Gallium-68, Fluorine-18, or Technetium-99m for PET/SPECT imaging, and therapeutic radioligands labeled with alpha or beta emitters like Lutetium-177, Yttrium-90, Actinium-225, or Lead-212 to deliver localized radiation directly to the tumor. The development of this technology is supported by the CORFO Innova Alta Tecnología 2024 grant and aims to advance precision medicine for advanced pancreatic cancer.

Other names: Cancer de Páncreas: Terapia de Precisión con Radioligandos CaPTeR

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on CaPTeR radioligands.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CaPTeR radioligands.

Explore the full profile